Molecular diagnostics

Global Molecular Diagnostics Markets, Forecast to 2029: Technologies, Applications, Regulations and Companies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 19, 2020
Health, Biotechnology, Medical genetics, Medical tests, Companies, Life sciences, Branches of biology, Biotechnology, Molecular diagnostics, Agilent Technologies, Microarrays, Qiagen, CombiMatrix

The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.
  • The number of companies involved in molecular diagnostics has increased remarkably during the past few years.
  • A new edition in 1997 "Molecular Diagnostics I" as well as the next edition, "Molecular Diagnostics II" in 1999, were published by Decision Resources Inc, USA.

IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020

Retrieved on: 
Tuesday, May 19, 2020
Branches of biology, Biology, Biotechnology, Evidence-based medicine, Precision medicine, Systems biology, Medical genetics, Synthetic lethality, Forward-looking statement, Molecular diagnostics, Targeted therapy, Medicine

IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

Key Points: 
  • IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
  • IDEAYA is applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality which represents an emerging class of precision medicine targets.
  • This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events.
  • IDEAYA undertakes no obligation to update or revise any forward-looking statements.

Sepsis Diagnostics Market Worth $700 Million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, May 15, 2020
Branches of biology, Medicine, Clinical medicine, Biotechnology, Medical tests, Laboratory techniques, Nanotechnology, Molecular diagnostics, Assay, Microfluidics, Flow cytometry, Immunoassay

CHICAGO, May 15, 2020 /PRNewswire/ -- According to the new market research report "Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025", published by MarketsandMarkets, the global Sepsis Diagnostics Market size is expected to reach USD 700 million by 2025 from USD 429 million in 2019, at a CAGR of 8.5%.

Key Points: 
  • CHICAGO, May 15, 2020 /PRNewswire/ -- According to the new market research report "Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025", published by MarketsandMarkets, the global Sepsis Diagnostics Market size is expected to reach USD 700 million by 2025 from USD 429 million in 2019, at a CAGR of 8.5%.
  • The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the rising prevalence of sepsis across the globe.
  • Based on technology, the global sepsis diagnostics market is segmented into microbiology, molecular diagnostics, immunoassay, flow cytometry, microfluidics, and biomarkers.
  • Based on products, the global sepsis diagnostics market is segmented into blood culture media, assays & reagents, instruments, and software.

Sepsis Diagnostics Market Worth $700 Million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, May 15, 2020
Branches of biology, Medicine, Clinical medicine, Biotechnology, Medical tests, Laboratory techniques, Nanotechnology, Molecular diagnostics, Assay, Microfluidics, Flow cytometry, Immunoassay

CHICAGO, May 15, 2020 /PRNewswire/ -- According to the new market research report "Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025", published by MarketsandMarkets, the global Sepsis Diagnostics Market size is expected to reach USD 700 million by 2025 from USD 429 million in 2019, at a CAGR of 8.5%.

Key Points: 
  • CHICAGO, May 15, 2020 /PRNewswire/ -- According to the new market research report "Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025", published by MarketsandMarkets, the global Sepsis Diagnostics Market size is expected to reach USD 700 million by 2025 from USD 429 million in 2019, at a CAGR of 8.5%.
  • The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the rising prevalence of sepsis across the globe.
  • Based on technology, the global sepsis diagnostics market is segmented into microbiology, molecular diagnostics, immunoassay, flow cytometry, microfluidics, and biomarkers.
  • Based on products, the global sepsis diagnostics market is segmented into blood culture media, assays & reagents, instruments, and software.

Co-Diagnostics, Inc. Releases Prepared Remarks for First Quarter 2020 Conference Call

Retrieved on: 
Thursday, May 14, 2020
Health, Medical tests, Life sciences, Articles, Biotechnology, Molecular diagnostics, Emergency Use Authorization, Food and Drug Administration

SALT LAKE CITY, May 14, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.(Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, releases the prepared remarks for the Q1 2020 conference call scheduled for May 14, 2020.

Key Points: 
  • SALT LAKE CITY, May 14, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.(Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, releases the prepared remarks for the Q1 2020 conference call scheduled for May 14, 2020.
  • Due to overwhelming participation on the call, the conference call service was unable to accommodate the traffic.
  • In lieu of the call, the following remarks have been provided to update shareholders on recent corporate developments.
  • Following FDA emergency use authorization being granted just 3 days into the second quarter, orders for our test expanded even more vigorously.

Global Companion Animal Diagnostics Market (2019 to 2027) - COVID-19 Impact and Global Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 14, 2020
Veterinary, Health, Medical tests, Biotechnology, Molecular diagnostics, Companion

The "Companion Animal Diagnostics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology; Application; Animal Type; End User;and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Companion Animal Diagnostics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology; Application; Animal Type; End User;and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The growing prevalence of chronic diseases in pet animals and the increasing adoption of pets for companionship are the major factors driving the growth of the companion animal diagnostics market.
  • The global companion animal diagnostics market is segmented into technology, animal type, application, and end-user.
  • Based on technology, the companion animal diagnostics market is further segmented into immunodiagnostics, clinical biochemistry, hematology, urinalysis, molecular diagnostics, and others.

Erisyon Awarded Michael J. Fox Foundation Grant to Validate Methods for Early Parkinson's Detection

Retrieved on: 
Thursday, May 14, 2020
Medicine, Clinical medicine, Biology, Biomarkers, Biotechnology, Chemical pathology, The Michael J. Fox Foundation, Parkinson's disease, Pathology, Imaging biomarker, Molecular diagnostics

Erisyon will use the funds to deploy the power of single molecule protein sequencing for the detection and validation of biomarkers that have the potential for early detection of the disease.

Key Points: 
  • Erisyon will use the funds to deploy the power of single molecule protein sequencing for the detection and validation of biomarkers that have the potential for early detection of the disease.
  • "Understanding the molecular pathology of Parkinson's has been one of the major challenges facing researchers," said Luis Oliveria, Associate Director of Research Programs, The Michael J.
  • With this grant, the Erisyon team will test new methods that could provide clinicians with diagnostic tools for early identification of Parkinson's disease.
  • Fox Foundation, our study aims to quantify very accurately the biomarker for Parkinson's at a much earlier stage of the disease."

Agendia to Showcase New Data at ASCO 2020 That Further Stratifies Breast Cancer Patients for More Precise Therapy Recommendations

Retrieved on: 
Thursday, May 14, 2020
RTT, Medicine, MammaPrint, Microarrays, Branches of biology, Clinical medicine, Molecular diagnostics, Breast cancer, Cancer, Symphony, Breast cancer classification

Data will underscore Agendia's mission to help guide the diagnosis and personalized treatment of breast cancer for patients throughout their treatment journey.

Key Points: 
  • Data will underscore Agendia's mission to help guide the diagnosis and personalized treatment of breast cancer for patients throughout their treatment journey.
  • Two other poster presentations will feature additional data sets from Agendia's ongoing multicenter, prospective, observational trial for patients with Stage I, II, and III breast cancer (FLEX).
  • Agendia is a molecular diagnostics company committed to improving clinical outcomes and informing the journey for patients with early stage breast cancer.
  • By developing evidence-based, novel genomic tests, Agendia aims to support the evolving clinical needs of breast cancer patients and their physicians.

Global Molecular Point Of Care Diagnostics Market Forecast 2019-2028

Retrieved on: 
Tuesday, May 12, 2020
Actuarial science, Compound annual growth rate, Mathematical finance, Non-Newtonian calculus, Academic disciplines, Molecular diagnostics, Articles

The global molecular point of care diagnostics market is projected to register growth at a CAGR of 14.90% during the forecast period, 2019-2028.

Key Points: 
  • The global molecular point of care diagnostics market is projected to register growth at a CAGR of 14.90% during the forecast period, 2019-2028.
  • As a result, the increasing demand for non-invasive diagnosis is projected to propel the global molecular point of care diagnostics market growth in the coming years.
  • The global molecular point of care diagnostics market is geographically segmented into Asia Pacific, Europe, North America, and the rest of the world.The region of North America is predicted to dominate the global market, while the Asia Pacific region is estimated to record the highest CAGR, by the end of the forecast period.
  • The factors attributed to the North America market prospects are technological advancements impacting the scope of molecular diagnostics, along with advancements in research and development projects.

HTG Molecular Diagnostics to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 13

Retrieved on: 
Monday, May 11, 2020
Branches of biology, Biotechnology, Molecular diagnostics, Precision medicine, Biology, GlobeNewswire, Ariz, Tucson, Arizona, Life sciences

TUCSON, Ariz., May 11, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the first quarter ended March 31, 2020 after the market close on Wednesday, May 13, 2020.

Key Points: 
  • TUCSON, Ariz., May 11, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the first quarter ended March 31, 2020 after the market close on Wednesday, May 13, 2020.
  • Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.